Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Inventory (2016 - 2025)

Historic Inventory for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $583000.0.

  • Guided Therapeutics' Inventory fell 833.33% to $583000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $583000.0, marking a year-over-year decrease of 833.33%. This contributed to the annual value of $633000.0 for FY2024, which is 15.82% up from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' Inventory is $583000.0, which was down 833.33% from $595000.0 recorded in Q2 2025.
  • Guided Therapeutics' Inventory's 5-year high stood at $648000.0 during Q3 2023, with a 5-year trough of $548000.0 in Q4 2022.
  • Its 5-year average for Inventory is $603315.8, with a median of $596000.0 in 2022.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 113725.49% in 2021, then crashed by 982.57% in 2022.
  • Guided Therapeutics' Inventory (Quarter) stood at $571000.0 in 2021, then fell by 4.03% to $548000.0 in 2022, then grew by 15.33% to $632000.0 in 2023, then rose by 0.16% to $633000.0 in 2024, then decreased by 7.9% to $583000.0 in 2025.
  • Its Inventory stands at $583000.0 for Q3 2025, versus $595000.0 for Q2 2025 and $633000.0 for Q1 2025.